The gastrointestinal microbiota is considered important in infl ammatory bowel disease (IBD) pathogenesis. Discoveries from established disease cohorts report reduced bacterial diversity, changes in bacterial composition, and a protective role for Faecalibacterium prausnitzii in Crohn ' s disease (CD). The majority of studies to date are however potentially confounded by the effect of treatment and a reliance on established rather than de-novo disease.
INTRODUCTION
Infl ammatory bowel disease (IBD) comprises a group of disorders characterized by chronic intestinal infl ammation with the main phenotypes being Crohn ' s disease (CD) and ulcerative colitis (UC). Th e incidence of IBD is rising, especially in children ( 1 -3 ) . Genetic discoveries implicate intracellular bacterial recognition (NOD2) and mechanisms of intracellular bacterial handling such as autophagy ( 4, 5 ) . Th e importance of the host innate immune response to bacteria highlighted by these discoveries has resulted in a renewed interest in the intestinal microbiota in IBD. Th e microbiota fulfi lls important roles in immunological development, defense against pathogens, production of exogenous enzymes, and salvage of dietary energy ( 6, 7 ) . Studies on the microbiota of IBD have revealed changes in its composition, which are now part of the disease pathogenesis paradigm. Th ese include an increase in bacterial numbers, a reduction in bacterial diversity, increases in the phyla Proteobacteria and Bacteroidetes, and a reduction in Firmicutes ( 8 -11 ) . Th e published evidence to date has relied on largely opportunistic studies of patients with established disease, providing a microbial snapshot of the chronic disease state at various time points aft er diagnosis. A signifi cant limitation of this approach however is that the major confounders of active treatment and disease chronicity make it impossible to interpret events following on from disease initiation ( 12 ) . Th e interrogation of the fecal microbiota in many studies also introduces a diffi culty, as the mucosal and fecal bacterial ecosystems are recognized as being distinct in health, but with little known in disease states ( 13, 14 ) .
Microbiota of
Pediatric IBD off ers an opportunity to explore these problems, since children are relatively free of additional signifi cant comorbidities and are generally treatment na ï ve at IBD diagnosis. For these reasons, we set up the " Bacteria in Infl ammatory bowel disease in Scottish Children Undergoing Investigation before Treatment " (BISCUIT) study.
METHODS

Patient recruitment, biopsy collection, and processing
Patients were recruited to the BISCUIT study from routine colonoscopy lists in each of three pediatric centers (Royal Aberdeen Children ' s Hospital, Aberdeen; Royal Hospital for Sick Children, Glasgow; and Ninewells Hospital, Dundee). An initial approach with study information was made either by post in advance of admission or on the day of admission, a minimum of 12 h in advance of the procedure. Patients under investigation in the pediatric centers were approached if the attending clinician deemed it possible that they would be found to have either IBD or a normal colon at colonoscopy. Patients were excluded if they had received systemic antibiotics or steroids in the 3 months before their colonoscopy or immunosuppression at any time, or if they had a previous diagnosis of IBD. All patients were investigated as per the Porto criteria, then diagnosed and phenotyped with reference to standard criteria ( 15 -18 ) .
Over 3 years the study recruited 100 children undergoing colonoscopy throughout Scotland in two categories, those with likely IBD, at fi rst presentation, with macroscopic colonic infl ammation ( n = 45) and those undergoing colonoscopy who subsequently had a normal colon macroscopically ( n = 55). Th e fi nal IBD cohort comprised 44 confi rmed IBD subjects (29 CD, 13 UC, and 2 IBD, type unclassifi ed). Th e remaining " likely IBD " (infl amed colon) subject had mild, non-specifi c chronic infl ammation in their distal colon on histopathology. Th is was insuffi cient to warrant a formal IBD diagnosis.
Biopsies were taken from a single site, from the distal colon in controls (rectum / sigmoid), or from the most distal infl amed site in IBD. In all, 2 -3 biopsies were collected using standard endoscopic forceps. Biopsies were collected into a sterile 1.5 ml Eppendorf container and placed immediately onto ice before transfer to − 80 ° C storage.
To explore bacterial diversity, 37 subjects were identifi ed for further analysis ( Table 1 ; Supplementary Table 1 ) . Twelve UC were included, all with distal colonic infl ammation. Th irteen CD patients were identifi ed with granulomatous change in their biopsy set, fi rmly supportive of their diagnosis, and distal colonic infl ammation in keeping with CD (and hence distal colonic biopsies) to match colonic site with the control and UC cohorts. Twelve controls were selected as most representative of " normal, " having both a macroscopically and a microscopically normal colon, matched as closely as possible for age and sex to the IBD groups. None of the controls have gone on to develop IBD with a mean time since endoscopy of 23 months (minimum 7 months).
DNA extraction of mucosal biopsies was performed using the commercially available Qiagen QIAamp Mini kit (Qiagen, Crawley, UK) with minor modifi cations ( 19 ) . A test PCR was performed as described previously with biopsy DNA utilizing primers universal for bacteria to confi rm the suitability of the DNA for further analysis ( 20 ) .
Ethical approval was granted by North of Scotland Research Ethics Service (09 / S0802 / 24) on behalf of all participating centers and written informed consent was obtained from the parents of all subjects. Informed assent was also obtained from older children who were deemed capable of understanding the nature of the study.
Th is study is publicly registered on the United Kingdom Clinical Research Network Portfolio (9633).
Preparation of samples for pyrosequencing
Biopsy DNA was quantifi ed by Nanodrop mass spectrophotometry before dilution to 25 ng / μ l. Initial PCR amplifi cation was undertaken with FastStart High Fidelity PCR reagents (Roche, Penzberg, Germany) utilizing a per-reaction mix of 50 ng of DNA template, 10 × FastStart High Fidelity Reaction Buff er with 90 nM MgCl 2 , 10 nM dNTPs, 10 pM Fusion Primer A, 10 pM Fusion Primer B, 5 U FastStart High Fidelity Enzyme Blend. Th e 16S rDNA primers were taken from Dethlefsen et al. ( 21 ) ; however, we utilized the 338f partnered with 1064r, spanning the V3 -V6 region of the 16S rRNA gene and providing a ~ 726-bp product. For the forward primer, two multiplex identifi ers (MID1 and MID2) were used to allow multiplexing of paired samples during sequencing. No identifi er was added to the reverse primer. Hence, the ~ 726-bp PCR product was fl anked by a 40-bp fusion primer / multiplex identifi er sequence at the forward end and a 30-bp fusion primer at the reverse end therefore resulting in a ~ 796-bp sequence. Th e fi nal primers were A-338f1 5 ′ -CCATCTCATCCCTGCGTGTCTCCGACTC AG ACGAGTGCGT ACTCCTACGGGAGGCAGCAG-3 ′ ; A-338f2 5 ′ -CCATCTCATCCCTGCGTGTCTCCGACTCAG ACGCTCG ACA ACTCCTACGGGAGGCAGCAG-3 ′ and B-1064r 5 ′ -CCTAT CCCCTGTGTGCCTTGGCAGTCTCAG CGACARCCATG CASCACCT-3 ′ (page-purifi ed primers by Sigma-Aldrich, Gillingham, UK) with the bold sections corresponding to fusion primers, the underlined sections multiplex identifi ers, and the standard text to the 16S primers.
PCR cycling conditions were taken from the modifi ed conditions of Dethlefsen and were briefl y as follows: 3 min at 94 ° C; 30 cycles of 30 s at 94 ° C, 45 s at 55 ° C, 60 s at 72 ° C; 2 min at 72 ° C ( 21 ) . Aft er confi rmation of successful PCR amplifi cation, products were 
Real-time PCR
Quantitative real-time PCR (RT-PCR) was performed as described previously ( 22 ) . Briefl y, standard curves consisted of 10-fold dilution series of amplifi ed bacterial 16S rRNA genes from reference strains. Samples were amplifi ed with universal primers against total bacteria and specifi c primers against Bacteroidetes , Firmicutes clostridial cluster IV, Firmicutes clostridial cluster XIVa, Enterobacteriaceae and Faecalibacterium prausnitzii ( Table 2 ).
Supplementary methods
Supplementary Methods contain additional detail on RT-PCR methodology, bioinformatic analysis of pyrosequencing data, and statistical analyses.
RESULTS
Pyrosequencing generated >1 million individual sequencing reads in total with a mean yield of 21,691 reads per subject after bioinformatic processing but before rarefaction ( Supplementary Table 2 ). Of the 37 subjects in the study, 2 did not meet the 10,000 read threshold and were excluded, 1 UC whose bacterial DNA amplified poorly and failed quality control for pyrosequencing and 1 CD who was sequenced as all other subjects, but who only yielded 739 reads. In all, 1 further subject (CD) was sequenced and rarefied alongside the final 34, but 99.9 % of their 11,000 reads were unmatched at phylum level. Thus, 34 subjects were ultimately represented by 11,000 rarefied reads after bioinformatic processing, allowing subjectto-subject comparison. The only resultant demographic change was a loss of significance in symptom duration between CD and controls ( Table 1 ) .
In all, 1 UC subject amplifi ed poorly by RT-PCR despite successful pyrosequencing of their sample yielding 24,240 reads. A further attempt at RT-PCR with 50 ng DNA template was also unsuccessful; therefore, this subject was not included in RT-PCR correlations ( n = 33) but was included in pyrosequencing analyses ( n = 34). Pyrosequencing fi ndings correlated with RT-PCR results to a 0.01 signifi cance level (Pearson coeffi cients: Bacteroidetes 0.624 ( n = 33), Firmicutes 0.571 ( n = 33), Proteobacteria 0.891 ( n = 20, restricted to those where Proteobacteria were above RT-PCR detection threshold)). Single asymptomatic patient undergoing colonoscopy for genetic risk of familial adenomatous polyposis coli. Next shortest symptom duration is 5 months.
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Bacterial diversity was signifi cantly reduced in CD when compared with controls by three distinct indices (Shannon, Simpson, and Phylogenetic Diversity). No signifi cant diff erence in bacterial diversity was noted between UC and controls by any of the fi ve indices tested ( Table 3 ) .
Phylum-level diversity comparisons revealed no statistically signifi cant diff erences for the three prevalent bacterial phyla of Bacteroidetes, Firmicutes, and Proteobacteria ( P = 0.142 -0.850, ANOVA; Figure 1a -c ; Table 4 ) and a signifi cant result only in the numerically small phylum Actinobacteria between CD and controls ( Table 4 ). Individual subject phylum-level diversity showed some variability, particularly within Proteobacteria in UC ( Figure 1d ). Interestingly, a greater proportion of IBD reads were unmatched at phylum level, although these did not reach significance. Diversity comparisons by RT-PCR also revealed no statistically signifi cant diff erences for Bacteroidetes , Clostridial Cluster XIVa or Enterobacteriaceae ( P = 0.215 -0.619, ANOVA; Table 4 ), but did demonstrate a signifi cant increase in Clostridial Cluster IV in CD vs. controls ( P = 0.029).
An additional ANOVA comparison was made between each of the three pairings (CD vs. Controls, UC vs. controls, and CD vs. UC) against the top 99.9 % of genus-level matches (78 genera). Of a possible 234 comparisons, only 7 achieved statistical significance. These were Faecalibacterium , CD>Controls (mean 1,841.1 ( ± 1,004.6) vs. 921.7 ( ± 794. ( Figure 2 ) . Th e diff erence between CD and UC did not reach statistical signifi cance by either method (pyrosequencing P = 0.16, RT-PCR P = 0.3).
To explore clustering within disease categories, principal components analysis (PCA) was undertaken on weighted Unifrac distances ( Figure 3 ). Interestingly, no distinct group clustering was observed within any phenotypic group. Although microbial diversity was signifi cantly reduced in CD, this was not refl ected by distinct clustering of CD subjects on PCA. 
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both the CD and UC samples were obtained from infl amed tissue; hence, the reduction is not simply an artifact of infl ammation. Interestingly, a similar reduction in bacterial diversity has recently been noted in the oral microbiota of children with CD, but not in those with UC or healthy children ( 24 ) . Adult studies examining biopsies from both active and quiescent UC suggest a reduction in bacterial diversity in the former ( 25, 26 ) . Our UC cohort have active infl ammation and are untreated, suggesting that the causative agent of a reduction in bacterial diversity is perhaps more complex than simply the presence of infl ammation. PCA, a useful method of comparing diversity between individuals and looking for disease-specifi c microbial clustering, showed no clear distinctions between each of the three phenotypes we have studied (controls, CD, and UC). Th e landmark paper by Frank et al. ( 27 ) utilizing PCA in adult IBD biopsies outlined nominal sample clusters between an IBD subset and a control subset, nevertheless the phenotypic distinction on PCA was not absolute. Others
DISCUSSION
Our data describe a previously unexplored epoch in IBD microbiology, namely the onset of disease in treatment na ï ve children. A single adult study at IBD onset noted a signifi cant diff erence in unclassifi ed Bacteroidetes between CD and both UC and control patients, but no other signifi cant phylum changes when intestinal biopsies were examined by denaturing gradient gel electrophoresis and clone libraries ( 23 ) . Our study remains unique in the IBD literature by addressing the mucosal microbiota at the onset of disease in a population of treatment na ï ve children utilizing a deep sequencing approach, corroborated by RT-PCR. Our data challenge the view that phylum-level changes are important in IBD etiology, cast doubt on the notion that a reduction in bacterial diversity occurs in UC, but fi rmly support this same hypothesis in CD, thus demonstrating an important microbial distinction between these two conditions. Our bacterial diversity results probably indicate a true reduction associated with CD, as such as Walker et al. ( 28 ) have shown clear distinctions between disease phenotype using similar methods. Th e lack of diff erentiation we have shown suggests evolution as disease enters chronicity, or perhaps that such diff erentiation is merely an artifact of disease-specifi c treatment strategies.
We propose that the current literature on IBD microbiology more accurately refl ects changes associated with disease chronicity, and as such should not be extrapolated to the onset of disease. Furthermore, the important issue of active treatment, which is problematic when studying established disease, adds an important confounder which is underemphasized in the published literature.
In our study, all subjects received stimulant bowel preparation before colonoscopy. Th is may have altered the microbial profi le of the colonic mucosa, however since the treatment was given to all, this would likely act equivalently between groups. Furthermore, the organisms least likely to be aff ected would be those with adherent properties, of most interest in the mucosal disease of IBD. In support of our approach, other investigators have demonstrated diff erences in the IBD microbiota despite prior bowel preparation ( 10, 29 ) . Finally, a study design where children undergo diagnostic colonoscopy under general anesthetic without adequate preparation would be ethically unacceptable. Related to this latter point, the controls in this study were children undergoing colonoscopy to investigate gastrointestinal symptoms. Th ey were not therefore strictly " healthy " controls; however, we have tried to address this by selecting only those with a macroscopically and microscopically normal colon for inclusion.
Although genetically similar ( 30 ) , there are important distinctions between adult and pediatric IBD with the latter being characterized by a more extensive phenotype ( 31 ) and, at least in the case of CD, by a distinct immunophenotype ( 32 ) . Environmental factors such as gastrointestinal microbial colonization may be etiological factors of relevance to this distinction; hence, it is entirely possible that pediatric IBD is defi ned by a unique microbial signature, distinct from the adult disease.
Irrespective of the lack of phylum-level changes seen in our results at diagnosis, it appears that fecal microbial changes can be used as a useful biomarker for disease progression in children with 
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than on gastrointestinal colonization per se . Two explanations might be increased gastrointestinal transit (diarrhea) and anorexia in active UC. Understanding the impact of such infl uences and separating them from true etiological factors is a signifi cant challenge in gastrointestinal community microbiology.
Perhaps of most interest, we demonstrated a signifi cant increase in F. prausnitzii in CD at diagnosis, in marked contrast with previous reports of a reduction in the species in adult CD ( 29, 34, 35 ) .
F. prausnitzii is likely to have an important role in CD; however, its role may be more complex than our current understanding. It is clear from the seminal study of Sokol et al. ( 34 ) that this single species is positively associated with an improved UC ( 33 ) . Th e study of Michail et al. ( 33 ) demonstrated alterations in the fecal microbiota of pediatric UC vs. healthy controls, but also showed that UC non-responders to steroid treatment demonstrated fewer phylotypes within their fecal samples compared with responders when examined by microarray. Th is study raises an interesting consideration regarding microbial fi ndings in IBD, since the alterations seen could refl ect either causation or proxy association; nevertheless, their clinical utility as a biomarker may be suffi cient alone to warrant their further exploration. Our own UC results were surprisingly similar to our normal colon control group, suggesting that the UC-specifi c fecal alterations described by Michail et al. may refl ect an infl uence on the fecal stream rather outcome in established adult CD, with the demonstration that reduction in the proportion of this bacterium in intestinal samples was associated with endoscopic recurrence of disease. Th e same paper demonstrated the anti-infl ammatory properties of the bacterium in both a human in vitro cell model and a murine in vivo colitis model ( 34 ) . Th e inference of course is that the reduction of F. prausnitzii in CD is not simply a proxy for worsening infl ammation / disease, but that the organism is an integral component of the anti-infl ammatory balance in health and its reduction may directly contribute to promotion of the disease state. Our data directly contradict this hypothesis. One possible explanation might be highlighted by Bacteroides fragilis , an organism found to be capable of initiating colitis in animal models ( 36 ) , but also of directing an anti-infl ammatory immune response ( 37, 38 ) . Individual components of the microbiota may thus fulfi ll diff ering roles under diff erent conditions. Whether the increase in F. prausnitzii seen in CD within our study represents a hitherto undescribed pro-infl ammatory role for the species, whether the early host / microbiota response to IBD induces proliferation of F. prausnitzii in an attempt to reverse the infl ammatory change or whether the changes seen here are a proxy for some other phenomenon remains to be explained.
A single study from Jia et al. ( 39 ) reported a correlation between clinical improvement and a reduction in fecal F. prausnitzii abundance in patients with CD who responded to enteral nutrition therapy. Th e authors explained their surprising F. prausnitzii observation by commenting that it may merely be an innocent bystander in CD. Our data using more robust methodology are the fi rst to demonstrate an increase in this bacterium at CD diagnosis, which suggests a more complex and integral role for F. prausnitzii in CD pathogenesis. Interestingly, the data of Willing et al. ( 29 ) , derived from pyrosequencing of fecal samples in established disease, demonstrated an increase in Faecalibacterium in colonic, but a reduction in ileal CD although the former was not elaborated fully on within the paper.
Enteral nutrition is widely used in the management of pediatric CD, achieving high rates of remission in all phenotypes ( 40 ) . Its mode of action remains to be explained fully, although published studies to date suggest that changes in the microbiota parallel clinical response ( 41 ) . A recent study demonstrated a reduction in fecal F. prausnitzii in healthy adults fed a low fi ber enteral feed ( 42 ) . Considering this paper in tandem with our results, one could hypothesize that enteral nutrition results in a temporary reduction of bacterial load, especially F. prausnitzii whose growth is known to be stimulated by acetate produced by other bacteria, as well as by substrates supplied from a normal balanced diet. Th is could in turn lead to a temporary remission from CD activity. Th is hypothesis would fi t with the transient nature of enteral nutrition-induced remission in pediatric CD, with 60 -70 % of patients relapsing within 12 months of cessation ( 43 ) .
Another possible mechanism is suggested by very recent evidence that F. prausnitzii , although hitherto regarded as a strict anaerobe, has the ability to use low concentrations of oxygen as an electron acceptor through extracellular electron transfer ( 44 ) . It is proposed that this ability may equip F. prausnitzii for survival at the interface between oxygenated and anaerobic zones close to the colonic wall, which appears consistent with the high representation of F. prausnitzii noted here in biopsy samples. Disturbance to the colonic mucosa and mucus layer in disease states is likely to aff ect local oxygen gradients, with consequences for F. prausnitzii populations.
Our study has generated novel and intriguing data especially with regard to F. prausnitzii however larger prospective followup studies, with serial sampling of the mucosal microbiota at diagnosis and at opportunistic times throughout treatment, would further improve our understanding of the microbiology of these chronic diseases. Such studies would lend important insight into longitudinal microbial changes and their relationship with the potential confounders outlined above, hopefully helping to explain the complexities of the IBD microbiota and important organisms such as F. prausnitzii , with direct implications for disease treatment. Th e recent publication of data from the Human Microbiome Project has clearly shown the abundance, diversity and physiological importance of our microbial cohabitants and provided scaff olding for future studies ( 45, 46 ) . A greater understanding of the microbial pathogenesis of IBD is now within our grasp.
